Review
doi: 10.1038/nrc951.
Bloodborne biomolecular markers in prostate cancer development and progression
Affiliations
- PMID: 12459730
- DOI: 10.1038/nrc951
Item in Clipboard
Review
Bloodborne biomolecular markers in prostate cancer development and progression
Nat Rev Cancer.
2002 Dec.
Abstract
Prostate cancer is notoriously difficult to treat, which makes its early detection a priority. Biomarkers have been used to diagnose and monitor prostate cancer for more than 50 years, and the discovery of the serum marker prostate-specific antigen (PSA) significantly altered the detection and management of prostate cancer. But imperfect correlation with cancer hinders the usefulness of PSA. The elucidation and validation of new biological markers of prostate cancer should aid detection, and improve the application of the available therapeutics.
Similar articles
-
Biomarkers for prostate cancer.J Cell Biochem. 2009 Sep 1;108(1):3-9. doi: 10.1002/jcb.22227. J Cell Biochem. 2009. PMID: 19507229 Review.
-
Blood biomarkers for prostate cancer detection and prognosis.Future Oncol. 2007 Aug;3(4):449-61. doi: 10.2217/14796694.3.4.449. Future Oncol. 2007. PMID: 17661720 Review.
-
Prognostic value of serum markers for prostate cancer.Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. doi: 10.1080/03008880510030941. Scand J Urol Nephrol Suppl. 2005. PMID: 16019759 Review.
-
Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.Nat Clin Pract Urol. 2005 Oct;2(10):482-91. doi: 10.1038/ncpuro0321. Nat Clin Pract Urol. 2005. PMID: 16474622 Review.
-
Are multiple markers the future of prostate cancer diagnostics?Clin Biochem. 2004 Jul;37(7):519-28. doi: 10.1016/j.clinbiochem.2004.05.016. Clin Biochem. 2004. PMID: 15234233 Review.
Cited by
-
Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer.Br J Cancer. 2004 Jun 14;90(12):2312-6. doi: 10.1038/sj.bjc.6601814. Br J Cancer. 2004. PMID: 15150588 Free PMC article.
-
The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells.Lab Invest. 2015 Mar;95(3):283-95. doi: 10.1038/labinvest.2014.165. Epub 2015 Jan 12. Lab Invest. 2015. PMID: 25581609
-
Locus-specific gene repositioning in prostate cancer.Mol Biol Cell. 2016 Jan 15;27(2):236-46. doi: 10.1091/mbc.E15-05-0280. Epub 2015 Nov 12. Mol Biol Cell. 2016. PMID: 26564800 Free PMC article.
-
Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Curr Top Med Chem. 2013;13(20):2551-61. doi: 10.2174/15680266113136660182. Curr Top Med Chem. 2013. PMID: 24066886 Free PMC article. Review.
-
REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer.Sci Rep. 2017 Mar 3;7:42795. doi: 10.1038/srep42795. Sci Rep. 2017. PMID: 28256535 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
